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Progesterone (P4) is synthesized in the ovary and acts directly on granulosa cells of
developing ovarian follicles to suppress their rate of mitosis and apoptosis. Granulosa cells
do not express nuclear progesterone receptor (PGR) but rather progesterone receptor
membrane component-1 (PGRMC1). PGRMC1 binds P4 and mediates P4’s actions, as
evidenced by PGRMC1 siRNA studies. PGRMC1 acts by binding plasminogen activator
inhibitor 1 RNA-binding protein and regulating gene expression. Specifically, PGRMC1
suppresses some genes that promote cell death (i.e., Bad, Caspase-3, Caspase-4). P4
regulates gene expression in part by inhibiting PGRMC1 binding to Tcf/Lef transcription
sites, thereby reducing Tcf/Lef transcriptional activity. Since Tcf/Lef transcription sites are
located within the promoters of genes that initiate mitosis and/or apoptosis (i.e., c-jun
and c-myc), P4-PGRMC1 mediated suppression of these Tcf/Lef regulated genes could
account for P4’s actions. PGRMC1 expression is also altered in women with polycystic
ovarian syndrome, premature ovarian failure and infertility. Collectively, these observations
support a role for PGRMC1 in regulating human ovarian follicle development.
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INTRODUCTION
Progesterone receptor membrane component 1 (PGRMC1) plays
a clinically important role in regulating ovarian function as
demonstrated by the fact that PGRMC1 levels are reduced in
some women with polycystic ovarian syndrome (Schuster et al.,
2010) or premature ovarian failure (Mansouri et al., 2008;
Schuster et al., 2010). In contrast PGRMC1 over expression
is associated with impaired follicular development in women
undergoing gonadotropin-induced ovulation and in vitro fertil-
ization as part of their infertility treatment (Elassar et al., 2012).
In infertile patients, the elevated levels of PGRMC1 were detected
within ovarian (granulosa/luteal) cells harvested at the time of
oocyte (egg) retrieval. Thus, the change in PGRMC1 expression
directly reflects altered ovarian function. Moreover, PGRMC1 is
highly expressed in granulosa cells of ovarian follicles of women
(Engmann et al., 2006) as well as in all mammalian ovaries thus
far examined including mice (Cai and Stocco, 2005), rats (Peluso
et al., 2006), monkeys (Bishop et al., 2012), and cows (Kowalik
and Kotwica, 2008; Luciano et al., 2011).
Interestingly, PGRMC1 is detected at the plasma membrane
and cytoplasm and occasionally in the nuclei of granulosa cells of
growing preantral and antral follicles (Peluso et al., 2006). This
expression pattern is consistent with PGRMC1 being a medi-
ator of progesterone’s actions in granulosa cells. Specially, the
ability of progesterone (P4) to slow ovarian follicular growth
has been demonstrated in hypophysectomized hamsters (Moore
and Greenwald, 1974), gonadotropin-primed hamsters (Kim
and Greenwald, 1987) rats (Buffler and Roser, 1974), mice
(Peluso et al., 1980), and monkeys (Dizerega and Hodgen,
1982). Given these findings, this mini review will focus on the
experimental evidence that supports a role for P4-PGRMC1 sig-
naling in regulating the granulosa cell functions of mitosis and
apoptosis.
PGRMC1 AS A MEDIATOR OF P4’S ACTIONS
The first characteristic of a mediator of P4’s action is the abil-
ity to bind P4 with high affinity. Although there are reports that
PGRMC1 does not bind P4, these studies assessed P4-binding to
bacterially-expressed PGRMC1 proteins (For review see Cahill,
2007). However, the bacterially-expressed PGRMC1 may not be
properly folded and therefore unable to bind P4. In contrast,
partially purified PGRMC1-fusion protein isolated from either
spontaneously immortalized granulosa cells (SIGCs) or human
granulosa/luteal cells (hGL5 cells) specifically binds P4 with
high affinity (Peluso et al., 2008, 2009; Figure 1A). In addition,
PGRMC1 siRNA treatment of SIGCs for 48 h depletes PGRMC1
mRNA levels to 5% of scramble control (Peluso et al., 2013).
Furthermore, depleting PGRMC1 levels results in a correspond-
ing decrease in the capacity of these cells to bind P4 (Peluso et al.,
2013). Thus, these two observations provide conclusive evidence
that PGRMC1 binds P4.
In addition to binding P4, PGRMC1 is an essential compo-
nent in the mechanism through which P4 regulates granulosa cell
function. This has been demonstrated by genetically depleting the
expression of PGRMC1. Once PGRMC1 is depleted, P4 no longer
inhibits apoptosis induced by serum withdrawal (Peluso et al.,
2008, 2009). While serum withdrawal has been a useful model
system to demonstrate a functional role for P4-PGRMC1 signal-
ing in regulating granulosa cell survival (Peluso et al., 2008, 2009),
it is limited in that SIGCs do not proliferate readily in serum-free
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FIGURE 1 | Progesterone (P4)-PGRMC1 interactions. (A) Shows a
ligand-binding analysis of 3H-P4 to partially purified PGRMC1-GFP fusion
protein. Specific 3H-P4-binding decreased with the addition of
non-radioactive P4. Hill plot analysis (inset) yielded a straight line with a
slope of 1.08, indicting that 3H-P4 specifically bound to PGRMC1-GFP in a
competitive and reversible manner (Data from Figure 6 from Peluso et al.,
2008). The effect of PGRMC1 siRNA on SIGC proliferation (B) apoptosis
(C) and the percentage of cells in the metaphase stage of the cell cycle
(D). ∗ Indicates a value that is significantly different (p < 0.05) from
scramble control (∅).
culture. Therefore, the role of P4-PGRMC1 signaling in mitosis
cannot be examined in the serum-free culture model.
To resolve this issue SIGCs were exposed to PGRMC1 siRNA
in media supplemented with steroid-free serum. After 48 h,
PGRMC1 levels are reduced to ≈5% of that observed after scram-
ble siRNA treatment. In the presence of steroid-free serum, P4
suppresses the rate of mitosis and apoptosis of SIGCs exposed
to scramble siRNA. In contrast depleting PGRMC1 reduces P4’s
ability to suppress both of these cellular functions (Figures 1B,C)
(Peluso and Griffin, unpublished). Also, depleting PGRMC1
accelerates the rate at which SIGCs enter metaphase, but this
increase in metaphase cells does not result in an increase in
the number of cells. Rather, the metaphase cells undergo apop-
tosis. These studies not only confirm the functionality of the
P4-PGRMC1 signaling pathway but also are consistent with
the concept that P4 activation of PGRMC1 slows that rate of
cell division to insure that mitosis occurs properly with fewer
granulosa cells undergoing apoptosis as a result of a “mitotic
catastrophe” (Peluso et al., 2012a).
To gain insight into how P4 and PGRMC1 control mitosis,
the rate at which SIGCs enter the metaphase stage of the cell
cycle was determined by culturing these cells with colchicine,
which arrests cells in metaphase. This study demonstrates that
P4 suppresses and depletion of PGRMC1 accelerates entry into
metaphase even in the presence of P4 (Figure 1D). Thus, P4 acti-
vation of PGRMC1 slows the rate of entry into the metaphase
stage of mitosis. Interestingly, PGRMC1 localizes to the mitotic
spindle and directly interacts with the major mitotic spindle pro-
tein, ß-tubulin, as revealed by in situ proximity ligation assay
(Lodde and Peluso, 2011) (Figure 2A). In addition P4 increases
the stability of the spindle microtubules. Since P4 slows the rate
of ß-tubulin disassembly, this prolongs the duration of metaphase
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FIGURE 2 | In (A) the co-localization of β-tubulin (green) and
PGRMC1 (red) in relationship to metaphase chromosomes (blue)
is shown in SKOV3 cell. Also shown is interaction between
PGRMC1 and β-tubulin as revealed by in situ Proximity Ligation
Assay (PLA). The presence of red fluorescent dots in the PLA assay
indicates that two proteins are in close proximity (i.e., interacting).
DNA is counterstained with DAPI (blue). Negative controls were
conducted and did not show any staining. (Images are from Figures
5 to 7 from Lodde and Peluso, 2011). (B) Shows the number of
antral follicles present in the ovaries of 22–25 day old control (+/+),
heterozygous (+/−), and homozygous (−/−) PGRMC1 mice. The
percentage of atretic follicles is shown at the base of each bar
graph (Data from Pru and Peluso, unpublished). (C) Is a model
illustrating a mechanism through which progesterone (P4) activates a
PGRMC1-dependent cascade that regulates the events that initiate
entry into the cell cycle. Note that a numbered blue call out box
identifies the sequence of events in this mechanism and the gray
triangle symbolizes increasing P4 levels within the cell. ∗p < 0.05.
and extends the length of the cell cycle (Lodde and Peluso,
2011). Taken together, these results suggest that P4 activation of
PGRMC1 slows the rate of mitosis at two sites by: (1) suppressing
the rate of entry into the cell cycle and (2) prolonging the dura-
tion of metaphase. How P4 activation of PGRMC1 influences the
rate at which the cells traverse the cell cycle at either of these sites
is not known.
Based on these in vitro experiments, it is hypothesized that
reducing the level of PGRMC1 would disrupt granulosa cell
proliferation and increase apoptosis, resulting in more ovarian
follicles undergoing atresia. This hypothesis would be supported
if an increase in atretic (dying) follicles and/or fewer antral folli-
cles were observed in PGRMC1 conditional knockout mice. We
have recently generated mice in which PGRMC1 was depleted
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from granulosa cells by mating floxed PGRMC1 mice with trans-
genic mice in which cre recombinase enzyme is expressed under
the control of the Amhr2 promoter. Using these mice a role
for PGRMC1 in regulating follicle growth is supported by the
observation that in immature mice with reduced PGRMC1 lev-
els (i.e., heterozygous mice; +/−) the number of antral follicles
is the same as controls but the percentage of atretic follicles is
higher (Figure 2B). Depleting PGRMC1 levels as in homozygous
PGRMC1 knockout mice (−/−) results in fewer antral follicles
(Figure 2B) (Pru and Peluso, unpublished observations). Since
the numbers of primordial, primary and preantral follicles are
not reduced, this implies that PGRMC1 plays a key role in pro-
moting the growth of ovarian follicles between the preantral and
antral stages of development. The precise mechanism through
which PGRMC1 promotes the development of preantral into
antral follicles is not defined by likely is due in part to P4 activa-
tion of a PGRMC1 mediated cell survival pathway (Peluso et al.,
2010).
These in vitro and in vivo studies together with the clinical
observations imply that P4-PGRMC1 signaling plays an impor-
tant role in ovarian follicle development by regulating granulosa
cell proliferation and apoptosis. As indicated one site of action
is at the mitotic spindle and more must be done to elucidate the
details related to this site of action. Equally important is themech-
anism through which P4 activation of PGRMC1 influences the
rate at which granulosa cell enter into the cell cycle.
PGRMC1 AND ITS CAPACITY TO BIND P4
It is likely that the first event in a PGRMC1-dependent signal
transduction pathway is P4-binding to PGRMC1. Unfortunately,
the P4-binding site within PGRMC1 has not been clearly defined.
PGRMC1 is composed of a single amino acid chain of 194
amino acids. The first 20 amino acids encode the extracellular
domain, amino acids 21–40 encode a transmembrane domain
and amino acids 70–170 represent a cytochrome P450 b5-
binding domain (Cahill, 2007). In addition there are sumoylation
sites at lysine residues 136, 187, and 193 (see http://sumosp.
biocuckoo.org/online.php). Chemical modification studies sug-
gest that the progestin-binding site is within the cytoplasmic
domain of PGRMC1 just distal to the transmembrane domain
(Falkenstein et al., 2001). Since P4 is membrane permeable, this
binding site should be relatively accessible to P4 even though it
resides on the cytoplasmic side of the membrane. Interestingly,
depleting any amino acid segment eliminates P4-binding, sug-
gesting that the entire PGRMC1 molecule is required for effective
P4-binding (Peluso et al., 2008). Clearly, more detailed studies
regarding the structural requirements for PGRMC1 to bind P4
are needed in order to resolve this important aspect of PGRMC1’s
mechanism of action.
PGRMC1 AND ITS INTERACTIONWITH PAIRBP1
The sequence of molecular events that occurs once P4 binds
PGRMC1 is not known. What is known is that the relation-
ship between P4 and PGRMC1 is not a simple ligand-receptor
interaction, because PGRMC1 also binds plasminogen activa-
tor inhibitor 1 mRNA-binding protein (PAIRBP1) (Peluso et al.,
2005, 2008, 2013) and P4 increases this interaction (Peluso et al.,
2013). Further, PAIRBP1-PGRMC1 interaction is essential for
P4-PGRMC1 signaling, since depleting PAIRBP1 attenuates P4’s
ability to inhibit apoptosis (Peluso et al., 2013). Interestingly,
depleting PAIRBP1 does not alter the expression or localization
of PGRMC1 nor does it limit the ability of granulosa cells to
bind P4 (Peluso et al., 2013). Thus, determining why disrupting
PAIRBP1-PGRMC1 interaction is vital for P4-PGRMC1 signaling
must be addressed in order to define the P4-PGRMC1 signaling
cascade.
To gain insight into this issue, the amino acid sequence
in PGRMC1 that promotes its interaction with PAIRBP1 was
recently identified. This was accomplished by making a series
of PGRMC1-GFP deletion mutations and using them in pull-
down assays (Peluso et al., 2008). From these studies, it is clear
that the PGRMC1 segment between amino acids 70 and 130
binds PAIRBP. In addition transfection of the 70–130 amino acid
sequence of PGRMC1 into either SIGCs or primary granulosa
cells disrupts the interaction between endogenous PGRMC1 and
PAIRBP1 and induces cells to rapidly undergo apoptosis even in
the presence of P4, PGRMC1, and PAIRBP1 (Peluso et al., 2013).
This further illustrates the importance of PAIRBP1-PGRMC1
interaction.
These pulldown studies also revealed that the PGRMC1-
GFP fusion protein without amino acids 131–194 binds more
PAIRBP1 than the full-length PGRMC1-GFP (Peluso et al.,
2008). Importantly, the 131–194 amino acid segment contains
all three sumoylation sites (lysine 136, 187, and 193) (Peluso
et al., 2012b). It is possible that PAIRBP1 functions as a scaf-
folding protein that brings PGRMC1 into close proximity to
sumoylating enzymes. This concept is based on the observa-
tion that PAIRBP1, also known as CGI-55, binds enzymes that
stimulate sumoylation including E3 SUMO ligases and SUMO-
activating enzyme subunit 2 (Lemos and Kobarg, 2006). Under
this scenario, non-sumoylated PGRMC1 would bind PAIRBP1
and become sumoylated, which would result in its released from
PAIRBP1. Although this aspect of PGRMC1’s mechanism of
action requires intensive testing, it implies that sumoylation is
an important posttranslational modification that influences the
events in the P4-PGRMC1 pathway that occur after PAIRBP1-
PGRMC1 interaction.
SUMOYLATION OF PGRMC1
To begin to validate this hypothesis, it is essential to demonstrate
that PGRMC1 is sumoylated. Western blots detect PGRMC1 as
a ≈22 kDa band but longer exposures often reveal several bands
that are >50 kDa (Peluso et al., 2010). These higher molecu-
lar weight bands represent different forms of PGRMC1 because
PGRMC1 siRNA treatment depletes these higher forms as well
as the lower band (Peluso et al., 2010). Moreover, some of the
higher molecular weight forms of PGRMC1 are sumoylated with
SUMO1 as demonstrated by a co-immunoprecipitation (Peluso
et al., 2012b). This is consistent with the finding that SUMO1 is
highly expressed in the mouse ovary (Shao et al., 2004). In addi-
tion to SUMO1, there are three other SUMO family members
(i.e., SUMO 2, 3, and 4) (Watts, 2007; Yan et al., 2010), which
may bind to PGRMC1. While there is considerably more research
required to characterize the sumoylation profile of PGRMC1,
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these co-immunoprecipitation studies confirm that PGRMC1 is
sumoylated, thereby supporting a role for PGRMC1 sumoylation
in the P4 signaling cascade.
While these co-immunoprecipitation studies are important,
they are rather incomplete. Since in silico analysis predictes that
PGRMC1 can be sumoylated at lysine residues 136, 187, and/or
193 (see http://sumosp.biocuckoo.org/online.php), an expres-
sion construct was made that encodes a PGRMC1-Flag fusion
protein in which the lysine within each of the three sumoyla-
tion sites was mutated to arginine (Sumo-PGRMC1-Flag), thus
eliminating the ability of the Sumo-PGRMC1-Flag fusion pro-
tein to be sumoylated. When SIGCs are transfected with either
SUMO-PGRMC1-Flag or wild-type PGRMC1-Flag and placed
under serum-free conditions for 5 h, fewer SUMO-PGRMC1-
Flag transfected SIGCs undergo apoptosis (i.e., 29 ± 3%) com-
pared to those cells that express wild type-PGRMC1-Flag (50 ±
5% apoptotic cells, n = 4, p < 0.01). Importantly, the percent-
age of SUMO-PGRMC1-Flag transfected SIGCs that undergo
apoptosis is similar to the percentage of wild type-PGRMC1-Flag
transfected cells observed after treatment with P4 (i.e., 25 ± 4%;
Peluso, unpublished observations).
Although it is not known whether all three sumoylation sites
are functional, the fact that mutating all of the putative sumoy-
lation sites enhances the ability of PGRMC1 to maintain SIGC
viability is consistent with the concept that sumoylation plays
an important role in modulating PGRMC1’s actions. The precise
role that sumoylation of PGRMC1 plays is under investigation.
Interestingly, SUMO-PGRMC1-Flag tends to be localized in
the cytoplasm compared to wild-type PGRMC1-Flag, which is
more equally distributed between themembrane/cytoplasmic and
nuclear fractions (Peluso, unpublished observation). Given that
PGRMC1-GFP without sumoylation sites binds more PAIRBP1
than wild-type PGRMC1-GFP, it is possible that the SUMO-
PGRMC1 remains tethered to PAIRBP1 in the cytoplasm. This
putative enhanced interaction between PAIRBP1 and SUMO-
PGRMC1 may account for the anti-apoptotic effects of SUMO-
PGRMC1, since PAIRBP1-PGRMC1 interaction is essential for
cell survival (Peluso et al., 2013).
In addition, sumoylation is an important posttranslational
modification that often promotes the transport of a protein from
cytoplasmic to the nucleus (Geiss-Friedlander and Melchior,
2007; Watts, 2007). This is consistent with the observation that
the higher molecular weight forms of PGRMC1 are located in
the nucleus (Peluso et al., 2010, 2012b). The nuclear localization
also implies that PGRMC1 may be involved in regulating gene
transcription.
PGRMC1’S NUCLEAR LOCALIZATION AND GENOMIC ACTION
Clearly, PGRMC1 sumoylation is an important event in the P4-
PGRMC1 signal cascade but this signal cascade has additional
components. This is evident because P4’s ability to prevent apop-
tosis requires RNA synthesis (Peluso et al., 2010). Since PGRMC1
is present within the nucleus (Peluso et al., 2010, 2012b), it is likely
that P4 activation of nuclear PGRMC1 regulates gene expres-
sion. To assess this, experiments were conducted to identify genes
whose expression is dependent on PGRMC1 (Peluso et al., 2010,
2012a). Although the expression of some genes was shown to
be PGRMC1-dependent (i.e., Bad, Caspase-3, Caspase-4) (Peluso
et al., 2010, 2012a), these studies are difficult to assess because
the expression of PGRMC1-dependent genes may not be the ini-
tial event that is triggered by P4-activated PGRMC1. Therefore,
studies were conducted to identify transcription factors, whose
activity was regulated by P4 activation of PGRMC1. A total of
48 transcription factors were screened and Tcf/Lef identified as a
transcription factor site whose activity is suppressed by P4 (Peluso
et al., 2012b).
To validate this transcription factor screen, filter and Tcf/Lef
luciferase reporter assays were used and these assays confirmed
that P4 decreases Tcf/Lef activity. Further, P4’s ability to sup-
press Tcf/Lef luciferase reporter activity is PGRMC1-dependent
because PGRMC1 siRNA attenuates P4’s ability to suppress
Tcf/Lef activity.
Interestingly, when PGRMC1 levels are increased by forcing
the expression of PGRMC1-Flag fusion protein, Tcf/Lef activity
is increased by 2-fold and P4 suppresses the increased Tcf/Lef
luciferase reporter activity induced by the PGRMC1-Flag (Peluso
et al., 2012b). Gel shift assays were also used to expand the
luciferase-based estimates of Tcf/Lef activity and demonstrate
that P4 decreases the amount of PGRMC1 bound to the Tcf/Lef
DNA probe. Further super shift assays reveal that PGRMC1-Flag
fusion protein binds to the Tcf/Lef DNA probe (Peluso, unpub-
lished observation). The ability of PGRMC1 to either enhance or
suppress Tcf/Lef activity in a P4-dependent manner is consistent
with concept that PGRMC1 acts as switch to either induce or sup-
press Tcf/Lef dependent gene expression. This concept is further
supported by the fact that Tcf/Lef-binding sites are found within
the promoter region of c-myc (Wierstra and Alves, 2008) and c-
jun (Mann et al., 1999), two genes that can initiate either mitosis
or apoptosis (Dang and Lewis, 1997).
A PUTATIVE MODEL OF THE P4-PGRMC1 SIGNAL
TRANSDUCTION PATHWAY AND ENTRY INTO THE CELL
CYCLE
Based on these studies, a preliminary mechanism can be outlined
that defines the P4-PGRMC1 signaling cascade in the context
of ovarian follicle development (Figure 2C). This mechanism
assumes that (1) the source of P4 is from either within indi-
vidual granulosa cells, secreted from granulosa cells within an
individual follicle or secreted from adjacent ovarian follicles or
corpora lutea, (2) regardless of the source, P4 acts on PGRMC1
that is present at or near the plasma membrane and within the
nucleus, and (3) P4’s actions are dose-dependent. With these
assumptions in mind, it is proposed that this signal transduc-
tion cascade is initiated by P4-binding to PGRMC1 at or near
the plasma membrane. This binding occurs at relatively low
P4 concentrations since the Kd for PGRMC1-binding to P4 is
between 10 and 40 nM (Peluso et al., 2008, 2009). P4-binding
likely alters the non-sumoylated form of PGRMC1 in such a way
as to facilitate its interaction with PAIRBP1, which is present
in cytoplasm. PAIRBP1 acts as a scaffolding protein bringing
sumoylation enzymes into close proximity with PGRMC1. As a
result, PGRMC1 is sumoylated and its ability to bind PAIRBP1 is
reduced, thereby releasing PGRMC1 and facilitating its transport
into the nucleus.
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Once in the nucleus, it is proposed that PGRMC1 interacts
with Tcf/Lef-binding sites that are within the promoters of early
immediate genes. PGRMC1 in the presence of mitogenic stimuli
enhances Tcf/Lef activity, which in turn stimulates the expression
of early immediate genes (e.g., c-myc and c-jun) and subsequently
induces the granulosa cell to enter the cell cycle. This mecha-
nism is consistent with the observations that in growing follicles
PGRMC1 is localized to the nucleus of about 30% of granulosa
cells, which is the same as the percentage of granulosa cells that
are in the S-phase of the cell cycle (Pedersen, 1970). However, as
these follicles grow, they synthesize more P4 (Roy and Greenwald,
1987). The increasing levels of P4 feeds back to reduce capacity of
nuclear PGRMC1 to bind these Tcf/Lef-binding sites. This would
make it more difficult for mitogenic stimuli to induce the expres-
sion of genes that initiate mitosis and would ultimately slow the
rate of granulosa cell proliferation. This is in agreement with the
finding that as antral follicle increase in size the frequency of gran-
ulosa cells in the S-phase of the cell cycle decreases (Pedersen,
1970) and steroid synthesis increases (Roy and Greenwald, 1987;
Hirshfield, 1991). How P4 alters PGRMC1 and thereby its inter-
action with the Tcf/Lef site is not known but may related to the
phosphorylation state of PGRMC1, since phosphorylation alters
the function of PGRMC1 (Neubauer et al., 2008). Thus, this pro-
posed negative feedback system could explain in part the inverse
relationship between rate of follicle growth and steroidogenesis
(Hirshfield, 1991).
While this proposed mechanism is incomplete at present, it is
proposed to provide a framework for future studies on P4’s action
in granulosa cells. Since PGRMC1 is expressed in numerous tis-
sues as outlined in several of the reviews in this issue, it is also
hoped that this putative mechanism will served as a guide to help
elucidate the mechanism of PGRMC1’s action in other tissues.
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